#Bristol Myers Squibb #RAAP #Rare Access Action Project

Bristol Myers Squibb Joins the Rare Access Action Project

In an important step toward enhancing patient care, Bristol Myers Squibb (BMS) has officially been welcomed as the newest member of the Rare Access Action Project (RAAP). This collaboration is aimed specifically at addressing the challenges faced by individuals living with rare diseases, which often hinder access to essential treatments and healthcare services.

Michael Eging, the Executive Director of RAAP, expressed enthusiasm over BMS's inclusion, highlighting the biopharmaceutical company's rich history of innovation and commitment to the well-being of patients facing serious health conditions. He emphasized that this partnership will bolster RAAP's efforts to create effective policy solutions that safeguard patient access to groundbreaking treatments and medical care.

Bristol Myers Squibb is recognized globally for its dedication to developing innovative medications catering to patients with severe illnesses. Their extensive portfolio includes treatments primarily in oncology, hematology, immunology, cardiovascular disease, and neuroscience. By harnessing scientific research and collaborative initiatives, BMS aims to improve patient outcomes significantly around the globe.

Mary Bordoni, Executive Director of Alliance Development at BMS, voiced the common struggle many patients with rare and serious illnesses encounter — the difficulty in accessing necessary treatments. With this partnership, BMS is optimistic about collaborating with patient advocates and other stakeholders to craft policies that facilitate patient access to these essential medicines.

Eging reinforced the notion that access challenges cannot be overcome in isolation.